Novavax COVID-19 vaccine authorized for U.S. teens

The Food and Drug Administration authorized Novavax Inc.'s /zigman2/quotes/202614340/composite NVAX +0.13% COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. /zigman2/quotes/205619834/composite MRNA -1.51% and BioNTech SE /zigman2/quotes/214419716/composite BNTX +0.26% , and received an emergency-use authorization by the FDA for adults in July. The vaccine still requires a policy recommendation for use by the Centers for Disease Control, which followed the FDA by about a week when authorizing the Novavax shot for adults. Novavax shares ticked 0.6% higher in late trading Friday, after the announcement; the stock has declined nearly 75% so far this year, as the S&P 500 index /zigman2/quotes/210599714/realtime SPX +0.15% has dropped 11.8%.

/zigman2/quotes/202614340/composite

Add to watchlist NVAX

Novavax Inc.

US : U.S.: Nasdaq

$ 7.70

+0.01 +0.13%

Volume: 2.95M

June 9, 2023 11:30a

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$663.69 million

Rev. per Employee

$682,155

/zigman2/quotes/205619834/composite

Add to watchlist MRNA

Moderna Inc.

US : U.S.: Nasdaq

$ 123.05

-1.89 -1.51%

Volume: 771,077

June 9, 2023 11:30a

P/E Ratio

10.69

Dividend Yield

N/A

Market Cap

$47.63 billion

Rev. per Employee

$3.83M

/zigman2/quotes/214419716/composite

Add to watchlist BNTX

BioNTech SE ADR

US : U.S.: Nasdaq

$ 109.25

+0.28 +0.26%

Volume: 151,448

June 9, 2023 11:29a

P/E Ratio

4.28

Dividend Yield

0.00%

Market Cap

$26.26 billion

Rev. per Employee

$2.79M

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

4,300.55

+6.62 +0.15%

Volume: 0.00

June 9, 2023 11:30a